The use of iron supplementation to reduce ESA dosing in Hemodialysis

Seminars in Dialysis

Volumn 26, Issue 5, 2013, Pages 534-536

  Shirazian, Shayan ^a   Grant, Candace ^a   Miller, Ilene ^b   Fishbane, Steven ^b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; EPO PROTEIN, HUMAN; ERYTHROPOIETIN; IRON DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN;

CHRONIC KIDNEY FAILURE; DIET SUPPLEMENTATION; HUMAN; IRON DEFICIENCY ANEMIA; METABOLISM; RENAL REPLACEMENT THERAPY; REVIEW;

ANEMIA, IRON-DEFICIENCY; DIETARY SUPPLEMENTS; ERYTHROPOIETIN; HEMATINICS; HUMANS; IRON COMPOUNDS; RECOMBINANT PROTEINS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84884702602     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/sdi.12105     Document Type: Article

References (35)

1. Centers for Medicaid and Medicare Services, 2005 Annual Report: ESRD clinical performance measures project. Am J Kidney Dis 48:S33, 2006
2. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019-32, 2009
3. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085-98, 2006
4. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-84, 2006
5. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-90, 1998.
6. Besarab A, Goodkin DA, Nissenson AR: The normal hematocrit study-follow-up. N Engl J Med 358:433-4, 2008
7. Food and Drug Administration: FDA Advisory Committee Briefing Document; Joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee; and errata, http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007–4315b1–01-FDA.pdf and http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007–4315b1–02-FDA-Errata%20.pdf, September 2007, accessed January 8, 2013
8. Fishbane S, Pollack S, Feldman H, Joffee MM: Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 4(1):57-61, 2009
9. Stancu S, Barsan L, Stanciu A, Mircescu G: Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 5:409-16, 2010
10. Eschbach JW, Cook JD, Scribner BH, Finch CA: Iron balance in hemodialysis patients. Ann Intern Med 87:710-3, 1977
11. Fishbane S, Maesaka JK: Iron management in end-stage renal disease. Am J Kidney Dis 29:319-33, 1997
12. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-6, 1995
13. K/DOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease 2006. Am J Kidney Dis 47(Suppl 3):S1, 2006
14. Agarwal R, Vasavada N, Sachs NG, Chase S: Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65:2279-89, 2004
15. Albaramki J, Hodson EM, Craig JC, Webster AC: Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 1:CD007857, 2012
16. Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, Gammaro L, Brocco G, Restivo G, Bernich P, Lupo A, Maschio G: The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16:1416-23, 2001
17. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK: The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7:2654-7, 1996
18. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J: A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60:2406-11, 2001
19. Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, St Pierre TG, Olynyk JK: Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 6:77-83, 2011
20. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahi NV, Rizkala AR, DRIVE Study Group: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18:975-84, 2007
21. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19(2):372-9, 2008
22. National Kidney Foundation: KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease 2012. Kidney Int Sup 2(4):v-335, 2012
23. Auerbach M, Al Talib K: Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 73:528-30, 2008
24. Besarab A, Kaiser JW, Frinak S: A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 34:21-8, 1999
25. Auerbach M, Pappadakis JA, Bahrain H, Auerbach SA, Ballard H, Dahl NV: Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol 86(10):860, 2011
26. U.S. Renal Data System, USRDS 2012 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012
27. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S: A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68:2846-56, 2005
28. Singh AK, Coyne DW, Shapiro W, Rizkala AR: Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 71:1163-71, 2007
29. Gotloib L, Silverberg D, Fudin R, Shostak A: Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 19:161-7, 2006
30. Ganz T, Nemeth E: Hepcidin and iron homeostasis. Biochim Biophys Acta 1823(9):1434-43, 2012
31. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Janklewicz P, Drahi G, Dahan H, Cohen Y: Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 125(10):991-9, 2012
32. Rooyakers T, Stroes E, Kooistra M, van Faassen EE, Hider RC, Rabelink TJ, Marx JJ: Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32(S1):9-16, 2002
33. Parkkinen J, von Bonsdorff L, Peltonen S, Grönhagen-Riska C, Rosenlöf K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 15(11):1827-34, 2000
34. Patruta SI, Edlinger R, Sunder-Plassmann G, Hörl WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9(4):655-63, 1998
35. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106(17):2212-7, 2002